Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-11-26
1999-08-24
Gupta, Yogendra N.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514258, 514269, 544230, 544316, 544330, 544331, 544332, A61K 31505, C07D23932
Patent
active
059425172
ABSTRACT:
This invention is directed to dihydropyrimidine compounds which are selective antagonists for human .alpha..sub.1C receptors and which have the structure: ##STR1## wherein A is aryl; R.sub.1, R.sub.2 and R.sub.3 are alkyl or heteroalkyl; R.sub.4 is heterocyclic alkyl; and X is S, O or NR.sub.3. This invention also relates to use of these compounds for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human .alpha..sub.1C receptor is useful. The invention further provides pharmaceutical compositions comprising a therapeutically effective amount of such a compound and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 4684653 (1987-08-01), Taylor et al.
patent: 4845216 (1989-07-01), Taylor et al.
patent: 4855301 (1989-08-01), Atwal et al.
patent: 4882334 (1989-11-01), Shih et al.
patent: 4902796 (1990-02-01), Taylor et al.
patent: 4946846 (1990-08-01), Nomura et al.
patent: 5202330 (1993-04-01), Atwal et al.
Boer, R., et al., "(+)-Niguldipine binds with very high affinity to Ca.sup.2+ channels and to a subtype of .alpha..sub.1 -adrenoceptors," European Journal of Pharmacology--Molecular Pharmacology Section (1989) 172: 131-145 (Exhibit 6).
Wetzel, J.M., et al., "Discovery of .alpha..sub.1a -Adrenergic Receptor Antagonists Based on the L-Type Ca.sup.2+ Channel Antagonist Niguldipine" Journal of Medicinal Chemistry (1995) 38(10): 1579-1581 (Exhibit 7).
Atwal, K.S. et al., "Dihydropyrimidine Calcium Channel Blockers. 2. 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines," Journal of Medicinal Chemistry (1990), vol. 33, pp. 2629-2635.
Atwal, K.S. et al., "Dihydropyrimidine Calcium Channel Blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Orally Effective Antihypertensive Agents," Journal of Medicinal Chemistry (1991), vol. 34, pp. 806-811.
Atwal, K.S. et al., "Dihydropyrimidine Calcium Channel Blockers: 2-Heterosubstituted 4-Aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines" Journal of Medicinal Chemistry (1990), vol. 33, pp. 1510-1515.
Atwal, K.S. et al., "Substituted 1,4-Dihydropyrimidines. 3. Synthesis of Selectively Functionalized 2-Hetero-1,4-dihydropyrimidines," Journal of Organic Chemistry (1989), vol. 54, pp. 5898-5907.
Atwal, K.S. et al., "Synthesis of Substituted 1,2,3,4-Tetrahydro-6-Methyl-2-Thioxo-5-Pyrimidinecarboxylic Acid Esters," (1987), vol. 26, pp. 1189-1192.
Cho, H. et al, "Dihydropyrimidines: Novel Calcium Antagonists with Potent and Long-Lasting Vasodilative and Antihypertensive Activity," Journal of Medicinal Chemistry (1989), vol. 32, pp. 2399-2406.
D'Eletto, R.D. and Javitt, N.B. "Effect of Doxazosin on Cholesterol Synthesis In Cell Culture," Journal of Cardiovascular Pharmacology (1989), vol. 13, Supplement 2, pp. S1-S4.
McGrath, J.C. et al., "Alpha-Adrenoceptors: A Critical Review," Medicinal Research Reviews (1989), vol. 9, No. 4, pp. 407-533.
Rovnyak, G.C. et al., "Dihydropyrimidine Calcium Channel Blockers. 4. Basic 3-Substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic Acid Esters. Potent Antihypertensive Gents," Journal of Medicinal Chemistry (1992), vol. 35, pp. 3254-3263.
Spiers, J.P. et al., "UK-52,046 (a Novel .alpha..sub.1 -Adrenoceptor Antagonist) and the Role of .alpha.-Adrenoceptor Stimulation and Blockade on Atrioventricular Conduction," Journal of Cardiovascular Pharmacology (1990), vol. 16, pp. 824-830.
Triggle, D.J., "Dihydropyrimidine Calcium Channel Blockers. 2. 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines," Chemtracts--Organic Chemistry (Jan./Feb. 1991), pp. 68-72.
Zhan, G.-L. et al., "Bunazosin Reduces Intraocular Pressure By Increasing Uveoscleral Outflow In Rabbits," Investigative Ophthalmology and Visual Science (1993), vol. 34, Abst. No. 1133-49, p.928.
Chiu George
Dhar T. G. Murali
Gluchowski Charles
Marzabadi Mohammad R.
Nagarathnam Dhanapalan
Gupta Yogendra N.
Synaptic Pharmaceutical Corporation
White John P.
LandOfFree
5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-467212